Company Xeris Biopharma Holdings, Inc. Nasdaq
Equities
XERS
US98422L1070
Pharmaceuticals
Business Summary
Number of employees: 377
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Gvoke, Keveyis and Recorlev
93.6
%
| 109 | 99.1 % | 153 | 93.6 % | +40.36% |
Royalty, Contract and Other
6.4
%
| 1 | 0.9 % | 11 | 6.4 % | +971.07% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 110 | 100.0 % | 164 | 100.0 % | +48.68% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 60 | 01/05/01 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 05/21/05 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 01/21/01 |
John Shannon
PSD | President | 62 | 05/21/05 |
Ken Johnson
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/21/01 |
Allison Wey
IRC | Investor Relations Contact | - | - |
Kevin McCulloch
PRN | Corporate Officer/Principal | - | 01/18/01 |
Beth Hecht
LAW | General Counsel | 60 | 01/21/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 05/21/05 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 05/21/05 |
Marla Persky
BRD | Director/Board Member | 68 | 05/21/05 |
Paul Edick
CEO | Chief Executive Officer | 67 | 05/21/05 |
Garheng Kong
BRD | Director/Board Member | 49 | 01/21/01 |
John Schmid
BRD | Director/Board Member | 60 | 05/21/05 |
Director/Board Member | 65 | 05/21/05 | |
Dawn Halkuff
BRD | Director/Board Member | 53 | 05/21/05 |
Ricki Fairley
BRD | Director/Board Member | 67 | 27/23/27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 148,253,615 | 142,712,322 ( 96.26 %) | 0 | 96.26 % |
Company contact information
Xeris Biopharma Holdings, Inc.
1375 West Fulton Street Suite 1300
60607, Chicago
+
http://www.xerispharma.comSector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
-3.40% | 157B |